Scarica l'app Stockscreener
496.07
2.49%
12.04
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché VRTX Giù?
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$484.03
Aprire:
$487.11
Volume 24 ore:
986.81K
Relative Volume:
0.67
Capitalizzazione di mercato:
$125.91B
Reddito:
$12.34B
Utile/perdita netta:
$4.34B
Rapporto P/E:
29.41
EPS:
16.8685
Flusso di cassa netto:
$3.71B
1 W Prestazione:
+3.98%
1M Prestazione:
-5.01%
6M Prestazione:
+3.80%
1 anno Prestazione:
+32.06%
Intervallo 1D:
$482.10
$497.39
Intervallo di 1 settimana:
$465.51
$497.39
Portata 52W:
$362.50
$533.67
Vertex Pharmaceuticals Inc Stock (VRTX) Company Profile
Nome
Vertex Pharmaceuticals Inc
Settore
Industria
Telefono
(617) 341-6393
Indirizzo
50 NORTHERN AVENUE, BOSTON, MA
Compare VRTX vs REGN, ARGX, RVMD, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
VRTX
Vertex Pharmaceuticals Inc
|
496.07 | 121.57B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
784.36 | 69.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
865.04 | 55.61B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
205.15 | 39.98B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
348.27 | 33.81B | 5.76B | 514.49M | 1.10B | 4.4813 |
Vertex Pharmaceuticals Inc Stock (VRTX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-03-18 | Aggiornamento | Maxim Group | Hold → Buy |
| 2026-03-10 | Iniziato | Jefferies | Buy |
| 2026-03-10 | Reiterato | Oppenheimer | Outperform |
| 2026-02-13 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2026-01-28 | Ripresa | Barclays | Overweight |
| 2026-01-22 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2026-01-12 | Aggiornamento | Bernstein | Mkt Perform → Outperform |
| 2026-01-07 | Ripresa | UBS | Buy |
| 2026-01-06 | Aggiornamento | Wolfe Research | Peer Perform → Outperform |
| 2025-12-03 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2025-11-13 | Iniziato | Scotiabank | Sector Outperform |
| 2025-09-25 | Aggiornamento | Leerink Partners | Market Perform → Outperform |
| 2025-09-03 | Iniziato | Raymond James | Mkt Perform |
| 2025-08-06 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2025-05-07 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| 2025-05-06 | Downgrade | Leerink Partners | Outperform → Market Perform |
| 2025-04-22 | Ripresa | Cantor Fitzgerald | Overweight |
| 2025-02-12 | Aggiornamento | Canaccord Genuity | Sell → Hold |
| 2025-02-11 | Aggiornamento | Canaccord Genuity | Sell → Hold |
| 2025-01-30 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2024-12-20 | Reiterato | H.C. Wainwright | Buy |
| 2024-12-19 | Downgrade | Oppenheimer | Outperform → Perform |
| 2024-12-09 | Aggiornamento | Jefferies | Hold → Buy |
| 2024-11-14 | Iniziato | Citigroup | Buy |
| 2024-10-16 | Iniziato | Scotiabank | Sector Perform |
| 2024-10-10 | Ripresa | Raymond James | Mkt Perform |
| 2024-08-05 | Downgrade | Barclays | Overweight → Equal Weight |
| 2024-06-27 | Iniziato | Redburn Atlantic | Buy |
| 2024-04-11 | Aggiornamento | Evercore ISI | In-line → Outperform |
| 2024-02-15 | Iniziato | Wolfe Research | Outperform |
| 2024-02-06 | Downgrade | Evercore ISI | Outperform → In-line |
| 2024-02-02 | Downgrade | Bernstein | Outperform → Mkt Perform |
| 2024-01-31 | Downgrade | Maxim Group | Buy → Hold |
| 2024-01-31 | Downgrade | Robert W. Baird | Neutral → Underperform |
| 2024-01-24 | Downgrade | Canaccord Genuity | Hold → Sell |
| 2023-12-14 | Reiterato | RBC Capital Mkts | Sector Perform |
| 2023-05-30 | Iniziato | William Blair | Outperform |
| 2023-05-04 | Ripresa | Piper Sandler | Overweight |
| 2023-03-21 | Iniziato | Bernstein | Outperform |
| 2023-01-18 | Iniziato | Canaccord Genuity | Hold |
| 2023-01-17 | Aggiornamento | SVB Leerink | Mkt Perform → Outperform |
| 2022-12-19 | Downgrade | Jefferies | Buy → Hold |
| 2022-07-13 | Iniziato | Cantor Fitzgerald | Overweight |
| 2022-06-01 | Aggiornamento | Maxim Group | Hold → Buy |
| 2022-05-23 | Iniziato | SVB Leerink | Mkt Perform |
| 2022-05-06 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2022-05-03 | Aggiornamento | Morgan Stanley | Underweight → Equal-Weight |
| 2022-02-03 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2022-01-27 | Reiterato | JP Morgan | Overweight |
| 2022-01-27 | Reiterato | Morgan Stanley | Underweight |
| 2022-01-27 | Reiterato | RBC Capital Mkts | Outperform |
| 2022-01-27 | Reiterato | Stifel | Hold |
| 2022-01-27 | Reiterato | Wolfe Research | Outperform |
| 2022-01-20 | Aggiornamento | BMO Capital Markets | Market Perform → Outperform |
| 2021-12-09 | Iniziato | Wells Fargo | Overweight |
| 2021-11-19 | Iniziato | BMO Capital Markets | Market Perform |
| 2021-11-19 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2021-09-09 | Downgrade | Stifel | Buy → Hold |
| 2021-09-07 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| 2021-07-20 | Downgrade | SVB Leerink | Mkt Perform → Underperform |
| 2021-07-19 | Ripresa | Wolfe Research | Outperform |
| 2021-07-01 | Iniziato | Raymond James | Mkt Perform |
| 2021-06-11 | Downgrade | Daiwa Securities | Outperform → Neutral |
| 2021-02-23 | Aggiornamento | Robert W. Baird | Neutral → Outperform |
| 2021-02-02 | Reiterato | H.C. Wainwright | Buy |
| 2020-12-30 | Iniziato | Daiwa Securities | Outperform |
| 2020-11-30 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2020-11-20 | Iniziato | Bernstein | Outperform |
| 2020-10-28 | Iniziato | UBS | Buy |
| 2020-07-31 | Reiterato | H.C. Wainwright | Buy |
| 2020-07-08 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2020-04-30 | Reiterato | H.C. Wainwright | Buy |
| 2020-04-28 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2020-03-04 | Iniziato | Barclays | Overweight |
| 2020-01-31 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2019-11-19 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2019-11-12 | Iniziato | SunTrust | Buy |
| 2019-10-17 | Ripresa | BofA/Merrill | Buy |
| 2019-09-03 | Aggiornamento | Goldman | Neutral → Buy |
| 2019-08-01 | Downgrade | Needham | Buy → Hold |
| 2019-05-23 | Ripresa | Citigroup | Buy |
| 2019-05-21 | Iniziato | Credit Suisse | Outperform |
| 2019-04-12 | Iniziato | Evercore ISI | In-line |
| 2019-03-26 | Aggiornamento | William Blair | Mkt Perform → Outperform |
| 2019-03-19 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| 2019-02-06 | Downgrade | Maxim Group | Buy → Hold |
Mostra tutto
Vertex Pharmaceuticals Inc Borsa (VRTX) Ultime notizie
Vertex Pharmaceuticals Incorporated (VRTX) is Attracting Investor Attention: Here is What You Should Know - Yahoo Finance
Vanguard Health Care ETF Outperforms VanEck Biotech on Returns, Yield, and Fees - The Motley Fool
Vertex Gears Up to Report Q2 Earnings: What Can Investors Expect? - TradingView
Vertex Pharmaceuticals (VRTX) Earnings Expected to Grow: Should You Buy? - Yahoo Finance
Vertex Pharmaceuticals (VRTX) Projected to Announce Quarterly Earnings on Monday - MarketBeat
OMERS ADMINISTRATION Corp Has $8.39 Million Stock Position in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Lombard Odier Asset Management Switzerland SA Cuts Position in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Healthcare of Ontario Pension Plan Trust Fund Purchases 20,523 Shares of Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Sei Investments Co. Sells 230,797 Shares of Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Vertex Pharmaceuticals Inc (VRTX) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Vertex Pharmaceuticals Incorporated $VRTX Position Reduced by Cetera Investment Advisers - MarketBeat
Vertex Pharmaceuticals Incorporated $VRTX Shares Sold by Bank of Nova Scotia - MarketBeat
Vertex Pharmaceuticals (VRTX) Q1 2026 Earnings Call Transcript - Fortune
Vertex Pharmaceuticals Incorporated $VRTX Shares Sold by Renaissance Technologies LLC - MarketBeat
Vertex Pharmaceuticals Incorporated $VRTX Shares Bought by PNC Financial Services Group Inc. - MarketBeat
Arrowstreet Capital Limited Partnership Acquires 45,003 Shares of Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Vertex Pharma stock trades near record levels as cystic fibrosis franchise drives earnings growth - AD HOC NEWS
Form 4 Vertex Pharmaceuticals Inc For: 24 July By Investing.com - Investing.com South Africa
Vertex Pharmaceuticals Inc (VRTX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
VRTX|Vertex Pharmaceuticals Inc|Price:478.960|Chg%:+1.600 - TradingKey
VRTX|Vertex Pharmaceuticals Inc|Price:473.090| - TradingKey
VRTX|Vertex Pharmaceuticals Inc|Price:477.360|Chg%:+4.270 - TradingKey
Caxton Associates LLP Makes New Investment in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Gibbs Wealth Management Boosts Holdings in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Vertex Pharma stock trades near record territory as cystic fibrosis franchise drives earnings growth - AD HOC NEWS
CI Investments Inc. Reduces Holdings in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
First Trust Advisors LP Has $136.85 Million Stake in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Vertex Pharmaceuticals Inc (VRTX) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Vertex Pharmaceuticals (VRTX) EVP Amit Sachdev receives 8,251-share equity grant - Stock Titan
Vertex stock consolidates after strong Q1 2026 revenue growth - Ad-hoc-news.de
3 Healthcare Stocks with Competitive Advantages - Yahoo! Finance Canada
Missed AI, Memory Bull Run? Biotech May Be The Next Breakout Trade — But Retail Sentiment Has Never Been Lower - Yahoo Finance
Aureus Asset Management LLC Has $3.75 Million Stock Position in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Vertex Pharmaceuticals Inc (VRTX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Vertex Pharmaceuticals (VRTX) Sees a More Significant Dip Than Broader Market: Some Facts to Know - Yahoo Finance
Vertex was sole bidder in high-premium Crinetics acquisition - BioPharma Dive
Vertex Pharmaceuticals Inc. stock underperforms Wednesday when compared to competitors - MarketWatch
Vertex was only bidder for Crinetics in year’s second-highest M&A premium - Endpoints News
Madison Asset Management LLC Boosts Stake in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Danica Pension Livsforsikringsaktieselskab Takes $11.67 Million Position in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Vertex-Crinetics Pharmaceuticals deal faces Australian review - MLex
ABN Amro Investment Solutions Grows Holdings in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Andra AP fonden Has $10.67 Million Stock Position in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Former Vertex chief Jeff Leiden’s latest venture: a ‘smart’ toilet seat - The Boston Globe
Vertex Pharmaceuticals (NASDAQ:VRTX): An Affordable Growth Stock Balancing Strong Fundamentals With Reasonable Valuation - ChartMill
Vertex Pharmaceuticals Incorporated $VRTX Shares Sold by KBC Group NV - MarketBeat
Meeder Asset Management Inc. Buys 2,799 Shares of Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Morgan Stanley Downgrades Vertex Pharmaceuticals to Equalweight From Overweight, Adjusts PT to $15 From $19 - marketscreener.com
Dimensional Fund Advisors LP Buys 43,682 Shares of Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Baader Bank Aktiengesellschaft Sells 8,324 Shares of Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Why Vertex Pharmaceuticals (VRTX) Dipped More Than Broader Market Today - Yahoo Finance
Vertex Pharmaceuticals Inc Azioni (VRTX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Vertex Pharmaceuticals Inc Azioni (VRTX) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| McKechnie Duncan | EVP, Chief Commercial Officer |
Jul 02 '26 |
Sale |
519.00 |
1,541 |
799,779 |
11,001 |
| Liu Joy | EVP and Chief Legal Officer |
Jul 01 '26 |
Sale |
502.71 |
828 |
416,244 |
19,131 |
1.59%
1.17%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):